Marksans Pharma Limited (NSE:MARKSANS)

Marksans Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	4,958	4,033	3,824	2,064	2,122
Short-Term Investments	-	2,094	2,710	3,328	1,399	-
Trading Asset Securities	-	7.42	269.94	5.4	4.35	2.61
Cash & Short-Term Investments	7,060	7,060	7,013	7,158	3,467	2,124
Cash Growth	0.77%	0.67%	-2.03%	106.47%	63.19%	126.66%
Accounts Receivable	-	5,400	4,532	4,168	3,948	2,719
Other Receivables	-	144.04	106.62	48.5	43.7	1.02
Receivables	-	5,544	4,638	4,217	3,991	2,721
Inventory	-	8,455	6,179	4,847	4,244	4,043
Prepaid Expenses	-	302.63	251.26	198.04	159.83	-
Other Current Assets	-	679.24	543.05	332.57	149.34	140.04
Total Current Assets	-	22,041	18,625	16,753	12,012	9,028
Property, Plant & Equipment	-	8,954	6,811	3,869	3,423	2,540
Long-Term Investments	-	1.68	1.68	-	-	-
Goodwill	-	409.28	394.99	384.89	300.25	195.86
Other Intangible Assets	-	727.32	647.62	707.97	585.69	474.36
Long-Term Deferred Tax Assets	-	-	-	-	38.57	7.99
Other Long-Term Assets	-	262.74	329.41	189.13	41.62	41.58
Total Assets	-	32,396	26,810	21,904	16,401	12,288
Accounts Payable	-	3,057	2,683	2,306	2,001	1,687
Accrued Expenses	-	644.31	442.56	220.96	131.01	103.53
Short-Term Debt	-	230.85	290.91	415.88	362.92	187.4
Current Portion of Long-Term Debt	-	-	-	-	50	-
Current Portion of Leases	-	354.92	249.51	156.68	280.52	60.37
Current Income Taxes Payable	-	299.41	199.08	252.78	173.27	300.21
Other Current Liabilities	-	186.91	33.66	57.59	563.67	651.52
Total Current Liabilities	-	4,773	3,898	3,410	3,562	2,990
Long-Term Debt	-	-	-	-	-	50
Long-Term Leases	-	2,633	1,900	656.89	414.34	93.26
Long-Term Deferred Tax Liabilities	-	36.62	106.2	153.86	176.21	80.63
Other Long-Term Liabilities	-	9.73	6.63	9.3	2.83	6.94
Total Liabilities	-	7,503	5,950	4,253	4,171	3,235
Common Stock	-	453.16	453.16	453.16	409.31	409.31
Additional Paid-In Capital	-	5,045	5,045	5,045	1,732	1,751
Retained Earnings	-	17,358	13,827	10,913	8,230	6,487
Comprehensive Income & Other	-	1,813	1,326	1,040	1,651	217.68
Total Common Equity	24,669	24,669	20,651	17,452	12,023	8,865
Minority Interest	-	224.7	208.52	199.1	207.01	188.57
Shareholders' Equity	24,894	24,894	20,859	17,651	12,230	9,054
Total Liabilities & Equity	-	32,396	26,810	21,904	16,401	12,288
Total Debt	3,219	3,219	2,441	1,229	1,108	391.03
Net Cash (Debt)	3,841	3,841	4,572	5,929	2,359	1,733
Net Cash Growth	-15.87%	-16.00%	-22.88%	151.30%	36.10%	193.41%
Net Cash Per Share	8.49	8.48	10.09	14.27	5.76	4.23
Filing Date Shares Outstanding	452.07	453.16	453.16	453.16	409.31	409.31
Total Common Shares Outstanding	452.07	453.16	453.16	453.16	409.31	409.31
Working Capital	-	17,268	14,726	13,343	8,450	6,039
Book Value Per Share	54.44	54.44	45.57	38.51	29.37	21.66
Tangible Book Value	23,533	23,533	19,608	16,359	11,137	8,195
Tangible Book Value Per Share	51.93	51.93	43.27	36.10	27.21	20.02
Land	-	5.31	5.18	5.1	4.67	4.14
Buildings	-	2,815	2,287	1,633	1,511	1,318
Machinery	-	5,701	4,445	3,355	3,038	2,515
Construction In Progress	-	90	53.81	72.46	6.95	56
Leasehold Improvements	-	116.61	105.64	-	-	-

Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.